Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Its product pipeline primarily includes elesclomol, formerly STA-4783, which is in Phase III clinical trial for the treatment of metastatic melanoma, and about to enter Phase IIb clinical trial for the treatment of additional cancers. The company has a collaboration agreement with Glaxosmithkline for the development of elesclomol. Its other drug candidates include Apilimod (STA-5326), which is in Phase IIa clinical trial in patients with rheumatoid arthritis, as well as sponsors a Phase IIa clinical trial in patients with common variable immunodeficiency. In addition, it develops STA-9090, an Hsp90 inhibitor and STA-9584, which are in preclinical development; and Oral CRAC ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. Synta Pharmaceuticals was founded in 2000 and is based in Lexington, Massachusetts.